Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Opaleye Management Inc.
Form 13F · Q2 2026

Opaleye Management Inc.

CIK 1595855Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.1B
Reported book value
58
Positions
12
Quarters on record
Top 50
Positions

Opaleye Management Inc. — holdings

Top 50 positions of 58, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1LQDA Liquidia Corporation2.4M−3.8%$195M17.7%
2ETON Eton Pharmaceuticals Inc2.9M+0.0%$104M9.4%
3HROW Harrow Inc2.4M−15.3%$102M9.2%
4IRON Disc Medicine Inc855,000+103.1%$63M5.7%
5URGN Urogen Pharma Ltd1.4M+0.7%$53M4.8%
6APOGEE THERAPEUTICS INC Apogee Therapeutics Inc390,000+0.0%$52M4.7%
7MGTX Meiragtx Hldgs Plc3.5M+67.2%$48M4.3%
8SLGL Sol-Gel Technologies Ltd500,000+0.0%$37M3.4%
9RZLT Rezolute Inc6.3M+0.0%$33M3.0%
10TGTX Tg Therapeutics Inc535,000+0.0%$29M2.7%
11IMMX Immix Biopharma Inc2.3M—$24M2.2%
12CBIO Crescent Biopharma Inc.1.3M+0.5%$24M2.2%
13STOK Stoke Therapeutics Inc700,000+0.0%$23M2.1%
14ACOG Alpha Cognition Inc2.9M+13.0%$21M1.9%
15EWTX Edgewise Therapeutics Inc500,000+0.0%$20M1.8%
16RVMD Revolution Medicines Inc100,000+0.0%$19M1.7%
17GLUE Monte Rosa Therapeutics Inc745,000—$18M1.6%
18ALMS Alumis Inc550,000+0.0%$15M1.4%
19CDXS Codexis Inc6.8M+0.0%$15M1.4%
20REPL Replimune Group Inc1.4M—$15M1.4%
21XOMA ROYALTY CORPORATION Xoma Royalty Corporation338,374+12.8%$14M1.3%
22MBX Mbx Biosciences Inc260,000+0.0%$14M1.3%
23RYTM Rhythm Pharmaceuticals Inc122,500−0.4%$14M1.2%
24EDIT Editas Medicine Inc3.9M+100.4%$13M1.1%
25PTGX Protagonist Therapeutics Inc100,000+0.0%$12M1.1%
26CABA Cabaletta Bio Inc3.9M+180.0%$12M1.1%
27QTTB Q32 Bio Inc931,000−25.9%$12M1.1%
28ANNX Annexon Inc1.7M−26.5%$10M0.9%
29VSTM Verastem Inc1.8M—$7M0.6%
30ZNTL Zentalis Pharmaceuticals Inc1.4M+0.0%$7M0.6%
31RLMD Relmada Therapeutics Inc935,000+0.0%$6M0.6%
32OCUL Ocular Therapeutix Inc600,000+0.0%$6M0.5%
33TRVI Trevi Therapeutics Inc310,000−10.2%$6M0.5%
34BBOT Bridgebio Oncology Therapeut700,000+1213.8%$5M0.5%
35LYEL Lyell Immunopharma Inc344,025+334.9%$5M0.4%
36IRD Opus Genetics Inc1.1M+0.4%$5M0.4%
37FDMT 4D Molecular Therapeutics In334,437+197.8%$4M0.4%
38NTLA Intellia Therapeutics Inc250,000+2.0%$4M0.4%
39VYGR Voyager Therapeutics Inc1.2M+3.0%$4M0.4%
40BDSX Biodesix Inc180,000−24.4%$4M0.4%
41RCKT Rocket Pharmaceuticals Inc1.0M+4.7%$3M0.3%
42JBIO Jade Biosciences Inc145,000−66.1%$3M0.3%
43SNWV Sanuwave Health Inc306,140−68.8%$3M0.3%
44FBIO Fortress Biotech Inc890,000−14.6%$3M0.2%
45DERM Journey Med Corp350,000−63.5%$2M0.2%
46PHAT Phathom Pharmaceuticals Inc185,589—$2M0.2%
47INBX Inhibrx Biosciences Inc20,291—$2M0.2%
48ENTA Enanta Pharmaceuticals Inc125,000+0.0%$2M0.2%
49COAG Hemab Therapeutics Hldgs Inc47,652—$2M0.2%
50TRAX First Tracks Biotherapeutics65,000—$1M0.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.